RESUMO
The ability to provoke emesis is defined by the emetogenic potential of each antineoplastic agent and by individual prognostic factors that determine the risk for each patient. The risk of chemotherapy-induced emesis is increased for females, patients between the ages of 6 and 50, and patients who drink little or no alcohol. Other risk factors include susceptibility to motion sickness and high levels of anxiety. Patients with one or more risk factors may require antiemetic treatment typically prescribed for a highly emetogenic regimen, even when a chemotherapy regimen is considered moderately emetogenic. The 5-HT3 receptor antagonists are the most effective agents against chemotherapy-induced nausea and should become standard antiemetic therapy for high-risk patients. Knowledge of factors affecting emesis and the antiemetic agents available for treating high-risk patients are the keys to successful nursing management of emesis in patients receiving chemotherapy.
Assuntos
Antieméticos/uso terapêutico , Antineoplásicos/efeitos adversos , Monitoramento de Medicamentos/métodos , Avaliação em Enfermagem/métodos , Vômito/induzido quimicamente , Vômito/tratamento farmacológico , Atividades Cotidianas , Fatores Etários , Humanos , Enfermagem Oncológica/métodos , Fatores de Risco , Caracteres Sexuais , Fatores de Tempo , Vômito/enfermagemRESUMO
In a collaborative consultation model of speech-language service delivery, the treatment system is expanded beyond the traditional client-centered dyad. Further, services are provided in the context of the classroom rather than in the noncontextual environment of a therapy room, and treatment goals relate to aspects of the school, such as curriculum, classroom behavior, and social interactions with peers. The use of the model is illustrated with a child having a cognitive impairment.
Assuntos
Transtornos Cognitivos/terapia , Terapia da Linguagem , Distúrbios da Fala/terapia , Fonoterapia , Criança , Feminino , HumanosRESUMO
The chronopharmacokinetics of the orally administered antileukemic drugs, 6-mercaptopurine and methotrexate, were examined in 13 children with acute lymphoblastic leukemia (ALL) to establish if there is a pharmacokinetic basis for the lower relapse rate associated with administration of these agents in the evening. Children with ALL in complete remission had plasma drug concentrations monitored for 8 h following an oral dose of either methotrexate or 6-mercaptopurine administered in the morning (8 a.m.) and the evening (8 p.m.). Total drug exposure to oral methotrexate, as measured by the mean area under the plasma concentration-time curve (AUC), was 2.75 microM.h following the morning dose and 2.77 microM.h in the evening. For 6-mercaptopurine, the mean morning AUC (198 ng.h/ml) was higher than that following the evening dose (167 ng.h/ml) (p greater than 0.05); but compared to the wide interpatient variability observed with this drug, this 20% difference is not likely to be clinically significant. These results indicate that the suggested benefit of evening drug administration is not likely to be a result of diurnal variation in drug disposition.
Assuntos
Ritmo Circadiano , Mercaptopurina/farmacocinética , Metotrexato/farmacocinética , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamento farmacológico , Administração Oral , Criança , Esquema de Medicação , Humanos , Mercaptopurina/administração & dosagem , Metotrexato/administração & dosagem , Leucemia-Linfoma Linfoblástico de Células Precursoras/metabolismoRESUMO
The pharmacokinetics of subcutaneously administered methotrexate was studied as a parenteral alternative to oral administration. An initial feasibility study was performed in Rhesus monkeys comparing the subcutaneous route to intravenous (IV) injection and oral administration. The subcutaneous dose was completely absorbed and a sustained-release effect was observed when compared with the IV dose. No local or systemic toxicities resulted from subcutaneous methotrexate in the animals. Twelve children with acute lymphoblastic leukemia on maintenance therapy protocols prescribing either 7.5 mg/m2 biweekly or 40 mg/m2 weekly were also monitored after both a subcutaneous and an oral dose of methotrexate. Four children at the higher dosage level were also studied after an equal IV dose. The subcutaneous dose was again completely absorbed in these children at both dose levels, whereas the oral dose, which produced comparable plasma drug concentrations at the lower dosage level, resulted in a total drug exposure (area under the plasma concentration-time curve) that was one third that of the equal subcutaneous dose at the higher dosage level. No local or systemic toxicity was attributed to the subcutaneous methotrexate. Subcutaneous administration of methotrexate is well tolerated and well absorbed and appears to overcome the problems associated with oral administration, including variable absorption and saturation of the absorption mechanism with increasing doses.
Assuntos
Metotrexato/farmacocinética , Absorção , Administração Oral , Adolescente , Adulto , Animais , Criança , Pré-Escolar , Feminino , Humanos , Injeções Subcutâneas , Macaca mulatta , Masculino , Metotrexato/administração & dosagem , Metotrexato/sangue , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamento farmacológicoRESUMO
A pediatric Phase I and pharmacokinetic study of the lipophilic alkylating agent spirohydantoin mustard (SHM) was conducted in 23 patients. The dose-limiting toxicity of SHM was neurological with disorientation, delirium, or hallucinations occurring in 9 of 23 patients. These symptoms were partially reversible and preventable with physostigmine. In 17 patients who were evaluable for response to treatment (14 of whom had central nervous system malignancies), no objective tumor responses were observed. Pharmacokinetic evaluation of SHM revealed a t1/2 alpha of 1.7 +/- 0.7 min, t1/2 beta of 16 +/- 8.3 min, and total body clearance of 2134 +/- 735 ml/min/m2. Measureable peak plasma levels were less than 40% of that which produces cytotoxicity in vitro against monolayer cultures of rat 9L brain tumor. Over 90% of SHM was protein bound, greatly limiting the free drug available for central nervous system penetration. SHM cerebrospinal fluid to plasma ratios were less than 0.047. The above suggests that in spite of its lipophilicity, SHM may not reach clinically significant levels in the central nervous system at clinically tolerable doses.
Assuntos
Antineoplásicos/efeitos adversos , Hidantoínas/efeitos adversos , Compostos de Mostarda Nitrogenada/efeitos adversos , Adolescente , Adulto , Antineoplásicos/farmacocinética , Criança , Pré-Escolar , Avaliação de Medicamentos , Feminino , Humanos , Hidantoínas/farmacocinética , Masculino , Sistema Nervoso/efeitos dos fármacos , Compostos de Mostarda Nitrogenada/farmacocinética , Fisostigmina/uso terapêutico , Ligação ProteicaRESUMO
Trimetrexate, a new nonclassical antifolate, was evaluated in a phase I trial in children with refractory cancer including nine with acute leukemia and 21 with solid tumors. The drug was administered as an i.v. bolus injection weekly for three doses, and courses were repeated every 28 days. The dose ranged from 35 to 145 mg/m2. Thirty patients who received a total of 33 courses were evaluable for toxicity, including 19 who were evaluable for hematological toxicity. The maximally tolerated dose for patients with a solid tumor and leukemia was 110 mg/m2. The dose-limiting toxicities were myelosuppression, mucositis and a pruritic, diffuse maculopapular rash. Other side effects observed included transient, mild elevations of serum transaminases, mild nausea and vomiting, and a local phlebitis at the site of injection at higher dose levels. A single patient with delayed drug clearance had evidence of renal toxicity with a transient increase in serum creatinine. The pharmacokinetics of trimetrexate were studied in 25 patients over the entire dose range. There was considerable interpatient variability in total drug clearance (range 9.2 to 215 ml/min/m2) and half-life (2.1 to 20 h). There was a suggestion of a correlation between plasma concentration at 24 h and the development of hematological toxicity at the highest dose level. Trimetrexate was cleared primarily by biotransformation with renal clearance accounting for only 10% of total clearance. Two metabolites of trimetrexate which inhibit the enzyme dihydrofolate reductase were identified in the urine. One of these appears to be a glucuronide conjugate.
Assuntos
Antineoplásicos/efeitos adversos , Antagonistas do Ácido Fólico/efeitos adversos , Quinazolinas/efeitos adversos , Adolescente , Antineoplásicos/metabolismo , Criança , Pré-Escolar , Avaliação de Medicamentos , Antagonistas do Ácido Fólico/metabolismo , Glucuronatos/metabolismo , Humanos , Lactente , Cinética , Quinazolinas/metabolismo , TrimetrexatoAssuntos
Transformação Celular Neoplásica , Linfoma/genética , Proteínas de Neoplasias/genética , Oncogenes , Animais , Sequência de Bases , Células Cultivadas , Enzimas de Restrição do DNA , Genes , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Endogâmicos , Proteínas de Neoplasias/metabolismo , Hibridização de Ácido Nucleico , Transdução GenéticaRESUMO
A cellular transforming gene detected by transfection of mouse T-cell lymphoma DNA has been isolated by molecular cloning. This gene (designated Tlym-I) is homologous to a small conserved family of sequences present in normal mouse and human DNAs but is not related to any of the previously described viral or cellular transforming genes.